Cargando…

Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients

BACKGROUND: Evidences support social inequalities in cancer survival. Studies on hematological malignancies, and more specifically Acute Myeloid Leukemia (AML), are sparser. Our study assessed: 1/ the influence of patients’ socioeconomic position on survival, 2/ the role of treatment in this relatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Eloïse, Delpierre, Cyrille, Despas, Fabien, Bertoli, Sarah, Bérard, Emilie, Bombarde, Oriane, Bories, Pierre, Sarry, Audrey, Laurent, Guy, Récher, Christian, Lamy, Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6729078/
https://www.ncbi.nlm.nih.gov/pubmed/31488077
http://dx.doi.org/10.1186/s12885-019-6093-3
_version_ 1783449540560420864
author Berger, Eloïse
Delpierre, Cyrille
Despas, Fabien
Bertoli, Sarah
Bérard, Emilie
Bombarde, Oriane
Bories, Pierre
Sarry, Audrey
Laurent, Guy
Récher, Christian
Lamy, Sébastien
author_facet Berger, Eloïse
Delpierre, Cyrille
Despas, Fabien
Bertoli, Sarah
Bérard, Emilie
Bombarde, Oriane
Bories, Pierre
Sarry, Audrey
Laurent, Guy
Récher, Christian
Lamy, Sébastien
author_sort Berger, Eloïse
collection PubMed
description BACKGROUND: Evidences support social inequalities in cancer survival. Studies on hematological malignancies, and more specifically Acute Myeloid Leukemia (AML), are sparser. Our study assessed: 1/ the influence of patients’ socioeconomic position on survival, 2/ the role of treatment in this relationship, and 3/ the influence of patients’ socioeconomic position on treatment utilization. METHODS: This prospective multicenter study includes all patients aged 60 and older, newly diagnosed with AML, excluding promyelocytic subtypes, between 1st January 2009 to 31st December 2014 in the South-West of France. Data came from medical files. Patients’ socioeconomic position was measured by an ecological deprivation index, the European Deprivation Index. We studied first, patients’ socioeconomic position influence on overall survival (n = 592), second, on the use of intensive chemotherapy (n = 592), and third, on the use of low intensive treatment versus best supportive care among patients judged unfit for intensive chemotherapy (n = 405). RESULTS: We found an influence of patients’ socioeconomic position on survival (highest versus lowest position HR(Q5): 1.39 [1.05;1.87] that was downsized to become no more significant after adjustment for AML ontogeny (HR(Q5): 1.31[0.97;1.76] and cytogenetic prognosis HR(Q5): 1.30[0.97;1.75]). The treatment was strongly associated with survival. A lower proportion of intensive chemotherapy was observed among patients with lowest socioeconomic position (OR(Q5): 0.41[0.19;0.90]) which did not persist after adjustment for AML ontogeny (OR(Q5): 0.59[0.25;1.40]). No such influence of patients’ socioeconomic position was found on the treatment allocation among patients judged unfit for intensive chemotherapy. CONCLUSIONS: Finally, these results suggest an indirect influence of patients’ socioeconomic position on survival through AML initial presentation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-6093-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6729078
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67290782019-09-12 Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients Berger, Eloïse Delpierre, Cyrille Despas, Fabien Bertoli, Sarah Bérard, Emilie Bombarde, Oriane Bories, Pierre Sarry, Audrey Laurent, Guy Récher, Christian Lamy, Sébastien BMC Cancer Research Article BACKGROUND: Evidences support social inequalities in cancer survival. Studies on hematological malignancies, and more specifically Acute Myeloid Leukemia (AML), are sparser. Our study assessed: 1/ the influence of patients’ socioeconomic position on survival, 2/ the role of treatment in this relationship, and 3/ the influence of patients’ socioeconomic position on treatment utilization. METHODS: This prospective multicenter study includes all patients aged 60 and older, newly diagnosed with AML, excluding promyelocytic subtypes, between 1st January 2009 to 31st December 2014 in the South-West of France. Data came from medical files. Patients’ socioeconomic position was measured by an ecological deprivation index, the European Deprivation Index. We studied first, patients’ socioeconomic position influence on overall survival (n = 592), second, on the use of intensive chemotherapy (n = 592), and third, on the use of low intensive treatment versus best supportive care among patients judged unfit for intensive chemotherapy (n = 405). RESULTS: We found an influence of patients’ socioeconomic position on survival (highest versus lowest position HR(Q5): 1.39 [1.05;1.87] that was downsized to become no more significant after adjustment for AML ontogeny (HR(Q5): 1.31[0.97;1.76] and cytogenetic prognosis HR(Q5): 1.30[0.97;1.75]). The treatment was strongly associated with survival. A lower proportion of intensive chemotherapy was observed among patients with lowest socioeconomic position (OR(Q5): 0.41[0.19;0.90]) which did not persist after adjustment for AML ontogeny (OR(Q5): 0.59[0.25;1.40]). No such influence of patients’ socioeconomic position was found on the treatment allocation among patients judged unfit for intensive chemotherapy. CONCLUSIONS: Finally, these results suggest an indirect influence of patients’ socioeconomic position on survival through AML initial presentation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-6093-3) contains supplementary material, which is available to authorized users. BioMed Central 2019-09-05 /pmc/articles/PMC6729078/ /pubmed/31488077 http://dx.doi.org/10.1186/s12885-019-6093-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Berger, Eloïse
Delpierre, Cyrille
Despas, Fabien
Bertoli, Sarah
Bérard, Emilie
Bombarde, Oriane
Bories, Pierre
Sarry, Audrey
Laurent, Guy
Récher, Christian
Lamy, Sébastien
Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients
title Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients
title_full Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients
title_fullStr Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients
title_full_unstemmed Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients
title_short Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients
title_sort are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? results from a french longitudinal observational study among older patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6729078/
https://www.ncbi.nlm.nih.gov/pubmed/31488077
http://dx.doi.org/10.1186/s12885-019-6093-3
work_keys_str_mv AT bergereloise aresocialinequalitiesinacutemyeloidleukemiasurvivalexplainedbydifferencesintreatmentutilizationresultsfromafrenchlongitudinalobservationalstudyamongolderpatients
AT delpierrecyrille aresocialinequalitiesinacutemyeloidleukemiasurvivalexplainedbydifferencesintreatmentutilizationresultsfromafrenchlongitudinalobservationalstudyamongolderpatients
AT despasfabien aresocialinequalitiesinacutemyeloidleukemiasurvivalexplainedbydifferencesintreatmentutilizationresultsfromafrenchlongitudinalobservationalstudyamongolderpatients
AT bertolisarah aresocialinequalitiesinacutemyeloidleukemiasurvivalexplainedbydifferencesintreatmentutilizationresultsfromafrenchlongitudinalobservationalstudyamongolderpatients
AT berardemilie aresocialinequalitiesinacutemyeloidleukemiasurvivalexplainedbydifferencesintreatmentutilizationresultsfromafrenchlongitudinalobservationalstudyamongolderpatients
AT bombardeoriane aresocialinequalitiesinacutemyeloidleukemiasurvivalexplainedbydifferencesintreatmentutilizationresultsfromafrenchlongitudinalobservationalstudyamongolderpatients
AT boriespierre aresocialinequalitiesinacutemyeloidleukemiasurvivalexplainedbydifferencesintreatmentutilizationresultsfromafrenchlongitudinalobservationalstudyamongolderpatients
AT sarryaudrey aresocialinequalitiesinacutemyeloidleukemiasurvivalexplainedbydifferencesintreatmentutilizationresultsfromafrenchlongitudinalobservationalstudyamongolderpatients
AT laurentguy aresocialinequalitiesinacutemyeloidleukemiasurvivalexplainedbydifferencesintreatmentutilizationresultsfromafrenchlongitudinalobservationalstudyamongolderpatients
AT recherchristian aresocialinequalitiesinacutemyeloidleukemiasurvivalexplainedbydifferencesintreatmentutilizationresultsfromafrenchlongitudinalobservationalstudyamongolderpatients
AT lamysebastien aresocialinequalitiesinacutemyeloidleukemiasurvivalexplainedbydifferencesintreatmentutilizationresultsfromafrenchlongitudinalobservationalstudyamongolderpatients